[144] Supernus Pharmaceuticals, Inc. SEC Filing
Supernus Pharmaceuticals (SUPN) insider sale notice: An officer filed a Form 144 to sell 10,650 shares of common stock on NASDAQ through Morgan Stanley Smith Barney. The 10,650 shares were acquired and are to be sold following an exercise of stock options with cash payment on the same date. The filing also discloses prior 10b5-1 plan sales by the same person totaling 142,500 shares over the past three months, generating aggregate gross proceeds of approximately $5,995,737.40. The current proposed sale lists an aggregate market value of $472,008.00.
Avviso di vendita interna di Supernus Pharmaceuticals (SUPN): Un dirigente ha presentato un Modulo 144 per vendere 10,650 azioni ordinarie sul NASDAQ tramite Morgan Stanley Smith Barney. Le 10,650 azioni sono state acquisite e saranno vendute in seguito a un esercizio di stock option con pagamento in contanti nella medesima data. Il deposito rivela inoltre vendite precedenti ai sensi di un piano 10b5-1 da parte della stessa persona per un totale di 142,500 azioni negli ultimi tre mesi, che hanno generato proventi lordi complessivi di circa $5,995,737.40. La vendita proposta attuale indica un valore di mercato aggregato di $472,008.00.
Aviso de venta por parte de un insider de Supernus Pharmaceuticals (SUPN): Un directivo present贸 un Formulario 144 para vender 10,650 acciones ordinarias en NASDAQ a trav茅s de Morgan Stanley Smith Barney. Las 10,650 acciones fueron adquiridas y se vender谩n tras un ejercicio de opciones sobre acciones con pago en efectivo en la misma fecha. La presentaci贸n tambi茅n revela ventas previas bajo un plan 10b5-1 por parte de la misma persona por un total de 142,500 acciones en los 煤ltimos tres meses, generando ingresos brutos agregados de aproximadamente $5,995,737.40. La venta propuesta actual indica un valor de mercado agregado de $472,008.00.
Supernus Pharmaceuticals(SUPN) 雮措秬鞛� 毵る弰 韱奠: 頃� 鞛勳洂鞚� Morgan Stanley Smith Barney毳� 韱淀暣 NASDAQ鞐愳劀 氤错喌欤� 10,650欤茧ゼ 毵る弰頃橁赴 鞙勴暣 Form 144毳� 鞝滌稖頄堨姷雼堧嫟. 頃措嫻 10,650欤茧姅 鞀ろ啞鞓奠厴 頄夓偓搿� 旆摑霅橃棃鞙茧┌ 臧欖潃 雮犾鞐� 順勱笀 瓴办牅鞕� 頃粯 毵る弰霅� 鞓堨爼鞛呺媹雼�. 鞝滌稖靹滊電� 霕愴暅 霃欖澕鞚胳澊 歆�雮� 3臧滌洈 霃欖晥 10b5-1 瓿勴殟鞐� 霐半澕 齑� 142,500欤�毳� 毵る弰頄堨溂氅�, 攴鸽 鞚疙暅 齑� 毵れ稖鞎§潃 鞎� $5,995,737.40霛缄碃 氚濏瀳瓿� 鞛堨姷雼堧嫟. 順勳灛 鞝滌晥霅� 毵る弰電� 齑濎嫓臧�齑濎暋 $472,008.00鞙茧 旮办灛霅橃柎 鞛堨姷雼堧嫟.
Avis de vente d'initi茅 de Supernus Pharmaceuticals (SUPN) : Un dirigeant a d茅pos茅 un formulaire 144 pour vendre 10,650 actions ordinaires sur le NASDAQ via Morgan Stanley Smith Barney. Les 10,650 actions ont 茅t茅 acquises et seront vendues suite 脿 un exercice d'options sur actions avec paiement en esp猫ces 脿 la m锚me date. Le d茅p么t r茅v猫le 茅galement des ventes ant茅rieures effectu茅es par la m锚me personne dans le cadre d'un plan 10b5-1 totalisant 142,500 actions au cours des trois derniers mois, g茅n茅rant des produits bruts agr茅g茅s d'environ $5,995,737.40. La vente propos茅e actuelle indique une valeur de march茅 agr茅g茅e de $472,008.00.
Insider-Verkaufsmitteilung von Supernus Pharmaceuticals (SUPN): Ein leitender Angestellter hat ein Formular 144 eingereicht, um 10,650 Stammaktien 眉ber NASDAQ durch Morgan Stanley Smith Barney zu verkaufen. Die 10,650 Aktien wurden im Zuge eines Aus眉bens von Aktienoptionen erworben und sollen am selben Tag gegen Barzahlung verkauft werden. Die Meldung gibt au脽erdem fr眉here Verk盲ufe derselben Person im Rahmen eines 10b5-1-Plans in H枚he von insgesamt 142,500 Aktien in den letzten drei Monaten an, die Bruttoerl枚se von rund $5,995,737.40 erbracht haben. Der aktuell vorgeschlagene Verkauf weist einen aggregierten Marktwert von $472,008.00 aus.
- Disclosure compliance: Form 144 filed with broker and transaction details, indicating adherence to Rule 144 reporting requirements
- Use of 10b5-1 plans: Prior sales were executed under 10b5-1 arrangements, which supports preplanned, lawful selling activity
- Material insider selling: 142,500 shares sold in the past three months for ~$5,995,737.40, which is a notable volume and proceeds amount
- Additional proposed sale: 10,650 shares (market value listed as $472,008.00) increases aggregate insider dispositions recently
Insights
TL;DR: Insider is selling option-exercised shares; prior 10b5-1 sales were sizable but appear preplanned.
The notice shows 10,650 shares to be sold after an option exercise funded in cash, indicating monetization of vested compensation rather than open-market purchases. Prior 10b5-1 plan transactions over the past three months total 142,500 shares and roughly $6.0 million in proceeds, which is material in absolute terms and may affect short-term float and supply. This disclosure is transparent and follows Rule 144 procedures, but the cumulative insider selling level is noteworthy for investors monitoring insider activity.
TL;DR: Filing documents compliance with Rule 144 and references 10b5-1 sales; volume of sales is significant.
The Form 144 lists broker details and confirms the securities were acquired by option exercise and paid in cash, which supports the legitimacy of the sale under Rule 144. Multiple large 10b5-1 transactions in a short period increase governance scrutiny risk and could attract investor attention, though the presence of a trading plan suggests procedural compliance. No allegations or regulatory issues are stated in the filing.
Avviso di vendita interna di Supernus Pharmaceuticals (SUPN): Un dirigente ha presentato un Modulo 144 per vendere 10,650 azioni ordinarie sul NASDAQ tramite Morgan Stanley Smith Barney. Le 10,650 azioni sono state acquisite e saranno vendute in seguito a un esercizio di stock option con pagamento in contanti nella medesima data. Il deposito rivela inoltre vendite precedenti ai sensi di un piano 10b5-1 da parte della stessa persona per un totale di 142,500 azioni negli ultimi tre mesi, che hanno generato proventi lordi complessivi di circa $5,995,737.40. La vendita proposta attuale indica un valore di mercato aggregato di $472,008.00.
Aviso de venta por parte de un insider de Supernus Pharmaceuticals (SUPN): Un directivo present贸 un Formulario 144 para vender 10,650 acciones ordinarias en NASDAQ a trav茅s de Morgan Stanley Smith Barney. Las 10,650 acciones fueron adquiridas y se vender谩n tras un ejercicio de opciones sobre acciones con pago en efectivo en la misma fecha. La presentaci贸n tambi茅n revela ventas previas bajo un plan 10b5-1 por parte de la misma persona por un total de 142,500 acciones en los 煤ltimos tres meses, generando ingresos brutos agregados de aproximadamente $5,995,737.40. La venta propuesta actual indica un valor de mercado agregado de $472,008.00.
Supernus Pharmaceuticals(SUPN) 雮措秬鞛� 毵る弰 韱奠: 頃� 鞛勳洂鞚� Morgan Stanley Smith Barney毳� 韱淀暣 NASDAQ鞐愳劀 氤错喌欤� 10,650欤茧ゼ 毵る弰頃橁赴 鞙勴暣 Form 144毳� 鞝滌稖頄堨姷雼堧嫟. 頃措嫻 10,650欤茧姅 鞀ろ啞鞓奠厴 頄夓偓搿� 旆摑霅橃棃鞙茧┌ 臧欖潃 雮犾鞐� 順勱笀 瓴办牅鞕� 頃粯 毵る弰霅� 鞓堨爼鞛呺媹雼�. 鞝滌稖靹滊電� 霕愴暅 霃欖澕鞚胳澊 歆�雮� 3臧滌洈 霃欖晥 10b5-1 瓿勴殟鞐� 霐半澕 齑� 142,500欤�毳� 毵る弰頄堨溂氅�, 攴鸽 鞚疙暅 齑� 毵れ稖鞎§潃 鞎� $5,995,737.40霛缄碃 氚濏瀳瓿� 鞛堨姷雼堧嫟. 順勳灛 鞝滌晥霅� 毵る弰電� 齑濎嫓臧�齑濎暋 $472,008.00鞙茧 旮办灛霅橃柎 鞛堨姷雼堧嫟.
Avis de vente d'initi茅 de Supernus Pharmaceuticals (SUPN) : Un dirigeant a d茅pos茅 un formulaire 144 pour vendre 10,650 actions ordinaires sur le NASDAQ via Morgan Stanley Smith Barney. Les 10,650 actions ont 茅t茅 acquises et seront vendues suite 脿 un exercice d'options sur actions avec paiement en esp猫ces 脿 la m锚me date. Le d茅p么t r茅v猫le 茅galement des ventes ant茅rieures effectu茅es par la m锚me personne dans le cadre d'un plan 10b5-1 totalisant 142,500 actions au cours des trois derniers mois, g茅n茅rant des produits bruts agr茅g茅s d'environ $5,995,737.40. La vente propos茅e actuelle indique une valeur de march茅 agr茅g茅e de $472,008.00.
Insider-Verkaufsmitteilung von Supernus Pharmaceuticals (SUPN): Ein leitender Angestellter hat ein Formular 144 eingereicht, um 10,650 Stammaktien 眉ber NASDAQ durch Morgan Stanley Smith Barney zu verkaufen. Die 10,650 Aktien wurden im Zuge eines Aus眉bens von Aktienoptionen erworben und sollen am selben Tag gegen Barzahlung verkauft werden. Die Meldung gibt au脽erdem fr眉here Verk盲ufe derselben Person im Rahmen eines 10b5-1-Plans in H枚he von insgesamt 142,500 Aktien in den letzten drei Monaten an, die Bruttoerl枚se von rund $5,995,737.40 erbracht haben. Der aktuell vorgeschlagene Verkauf weist einen aggregierten Marktwert von $472,008.00 aus.
FAQ
What did the Form 144 filed for SUPN disclose?
How many shares did the insider sell in the past three months for SUPN?
What were the gross proceeds from recent insider sales reported in the filing?
How were the 10,650 shares being sold acquired?
Which broker and exchange are listed for the proposed sale?
